



OPEN ACCESS

Milky pleural effusion in a neonate and approach to investigating chylothorax

Udara Dilrukshi Senarathne ^{1,2}, Ranmali Rodrigo,³
Bolonghoge Krishantha Trixy Priyankara Dayanath²

¹Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka

²Department of Chemical Pathology, Colombo North Teaching Hospital, Ragama, Sri Lanka

³Department of Paediatrics, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka

Correspondence to

Dr Udara Dilrukshi Senarathne; udara.senarathne@sjp.ac.lk

RR and BKTPD contributed equally.

Accepted 29 August 2021

SUMMARY

Neonatal chylothorax is a rare presentation leading to significant respiratory distress, thus requiring timely diagnosis. A preterm neonate was resuscitated and ventilated, following which she clinically improved but subsequently developed respiratory distress with a right-sided pleural effusion. Interestingly, thoracentesis fluid appeared 'milky' with elevated triglycerides and lymphocytes, suggesting chylothorax. As fluid triglyceride level was lower than the established diagnostic criterion for chylothorax (1.24 mmol/L), a high fluid-to-serum triglyceride ratio was used as a surrogate diagnostic marker, later confirmed by lipoprotein electrophoresis. As observed in the index patient, a critically ill neonate would have a lower-than-average fat intake leading to less chylomicron production, thus lower triglyceride levels in chyle than expected, which may still fail to meet the amended cut-off limit. This case highlights the challenges in diagnosing neonatal chylothorax due to the lack of age-specific triglyceride levels in chyle and low oral fat intake in critically ill patients.

BACKGROUND

Chylothorax is a rare cause of pleural effusion due to the extravasation of chyle from the thoracic duct or its tributaries. Neonatal chylothorax has an incidence of 1 in 5775 to 1 in 100 000 live births but can be considered the most common form of pleural effusion encountered in the perinatal period.^{1–5} The diagnosis of chylothorax is based on the demonstration of chylomicrons through elevated triglyceride levels in the pleural fluid above the established cut-off limit of 1.24 mmol/L (110 mg/dL) and elevated lymphocytes (>1000 cells/ μ L) on the fluid microscopy.^{6–8} However, the absence of age-specific cut-off limits for triglyceride levels in the chyle and dependence of chyle triglyceride on oral fat intake pose a challenge in diagnosing chylothorax in neonates, as observed in the preterm neonate with a milky pleural effusion reported by us.

CASE PRESENTATION

A female infant was born at 25 weeks of gestation, with a birth weight of 665 g by vaginal breech delivery to a 36-year-old mother of one child. The mother had pregnancy-induced hypertension (treated with nifedipine), and received appropriate antenatal steroids. She went into preterm labour at the onset of which the cervical cerclage was removed, giving birth to an infant who was floppy at birth, with no spontaneous breathing but with a heart rate >100/min (Apgar score: 6¹, 8⁵, 9¹⁰).

The infant was intubated shortly after birth due to increased work of breathing and subsequently received two doses of surfactant. Her chest X-ray on day 1 showed evidence of surfactant deficiency but no pleural effusion (figure 1A). She was not dysmorphic, and the remainder of her physical examination was normal.

The baby was started on trophic feeds with expressed breast milk (EBM) on day 2, and gradually increased to full feeds by day 5. Parenteral nutrition was not used due to the unavailability of custom preparations required to manage the infant's hyperglycaemia in the first few days. The infant had a late onset of *Coliform* sepsis from day 3 but remained stable respiratory-wise on conventional ventilation with a minimal increase in baseline oxygen requirement. However, over days 9 and 10, there was a deterioration in the respiratory status, with reduced air entry noted on the right side. On day 10, a right-sided pleural effusion was confirmed on chest X-ray (figure 1B), and a thoracentesis was performed for therapeutic and diagnostic purposes due to the significant respiratory distress caused by the effusion. Interestingly, 14 mL of 'milky white' fluid (figure 2A) was drained, subsequently correcting the desaturations along with radiological improvement (figure 1C). A tentative diagnosis of right-sided chylothorax was made based on clinical and radiological findings supported by the elevated fluid-to-serum triglyceride ratio, elevated fluid triglyceride-to-cholesterol ratio and lymphocytosis in the pleural fluid. The baby was kept nil-by-mouth, omitting EBM, and intravenous fluids were started. In addition, an intercostal tube was placed on the right side.

INVESTIGATIONS

The initial investigations revealed compensated respiratory acidosis, anaemia and hyperbilirubinaemia, and the infant later developed increased serum creatinine, thrombocytopenia and persistent hyperglycaemia with elevated inflammatory markers (table 1). The blood culture at birth was sterile.

Due to nasogastric feeding of EBM and the 'milky' nature of the pleural fluid, possible extravasation of breast milk from a perforated oesophagus was considered as one of the differential diagnoses prior to the aspirate being confirmed as chyle. The biochemical analysis of pleural fluid using EBM as the positive control showed that the EBM was strongly positive (figure 2B) for Benedict's test owing to its high lactose level; in contrast, pleural



© BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Senarathne UD, Rodrigo R, Dayanath BKTP. *BMJ Case Rep* 2021;**14**:e245576. doi:10.1136/bcr-2021-245576




Figure 1 (A) Chest X-ray soon after birth showing ground-glass appearance with air bronchogram on bilateral lung fields. (B) Chest X-ray on day 10 with obliteration of the right-sided costophrenic angle. (C) Chest X-ray following thoracentesis indicating resolution of right-sided pleural effusion.

fluid had only trace amounts of reducing substances (figure 2C). This observation excluded the possibility that the ‘milky’ pleural effusion was extravasated EBM. The biochemical analysis of thoracentesis fluid revealed elevated fluid triglyceride of 0.64 mmol/L (table 2), with a field full of lymphocytes on microscopy (figure 3), suggestive of chylothorax. Moreover, the fluid-to-serum triglyceride ratio was 1.9, with an elevated fluid triglyceride-to-cholesterol ratio indicating the chylous nature of the fluid.

Because the fluid triglyceride level failed to meet the established criterion for the diagnosis (1.24 mmol/L), we decided to conduct the gold standard lipoprotein electrophoresis to confirm the diagnosis of chylothorax. The pleural fluid was prestained with Sudan black and subjected to lipoprotein electrophoresis, which demonstrated no electrophoretic mobility (figure 4), confirming the presence of chylomicrons in the thoracentesis fluid. Thus, the diagnosis of right-sided chylothorax was confirmed, although an underlying cause for the chylothorax could not be ascertained definitively; birth trauma due to vaginal breech delivery was a probability.

DIFFERENTIAL DIAGNOSIS

The finding of a ‘milky’ pleural fluid in a neonate could be due to chylothorax, empyema, leakage of lipid in parenteral nutrition fluid from a central line or extravasated milk from a perforated oesophagus. The biochemical and microscopic analysis of thoracentesis fluid excluded empyema and milk extravasation into the pleural cavity. Although pseudo-chylothorax is a principal differential diagnosis under ‘milky’ effusions, it was considered unlikely in this patient due to the acute nature of the




Figure 2 (A) Thoracentesis fluid, (B) strongly positive Benedict’s test on expressed breast milk, (C) weakly positive Benedict’s test on thoracentesis fluid.

presentation, and it was further excluded by the low cholesterol levels observed in the pleural fluid.

Possible causes for chylothorax in a neonate could be congenital or acquired in nature. However, congenital pathologies were considered less likely in this patient due to the prolonged latency of 10 days before developing the chylothorax and the absence of dysmorphism and other anomalies. In addition, chromosomal disorders associated with chylothorax—Down and Turner syndromes—were excluded by karyotyping. Therefore, perinatal trauma due to vaginal breech delivery, resulting in damage to the thoracic duct with the accumulation of chyle once enteral feeds were established, was considered the most plausible cause of chylothorax in the index patient, based on the clinical presentation.

TREATMENT

The respiratory distress of the neonate was managed as mentioned above, while umbilical venous and arterial accesses were obtained soon after birth. Empirical antibiotic treatment with benzylpenicillin and gentamicin was started from day 1 of life, where as meropenem, flucloxacillin, and sulbactam were added based on the antibiotic sensitivity of the blood cultures. The neonate required inotropic support with dobutamine over the first 2 days. Her initial haemoglobin was 76 g/L (no antepartum haemorrhages and the infant’s cranial ultrasound scan was normal), for which packed red cells were administered (post-transfusion Hb 189 g/L), while thrombocytopenia ($67 \times 10^9/L$) was managed with platelet transfusions. The Coomb’s negative neonatal jaundice was managed with phototherapy. A summary of the investigation findings with the antibiotic treatment is given in table 3.

Table 1 Summary of investigation results within the first 48 hours of life

Parameter	Value	Reference limits	
Haematological parameters	Haemoglobin	76 g/L	140–240
	White blood cells	$27.28 \times 10^9/L$	3.1–21.6
	Neutrophils	68%	15–78
	Lymphocytes	27%	15–75
	Platelets	$220 \times 10^9/L$	152–472
Liver parameters	Aspartate transaminase	68 U/L	<35
	Alanine transaminase	18 U/L	<35
	Total bilirubin	221 $\mu\text{mol/L}$	<205
	Albumin	21 g/L	28–42
	Globulin	11 g/L	18–28
Electrolytes and renal parameters	Creatinine	131 $\mu\text{mol/L}$	27–88
	Sodium	138 mmol/L	130–145
	Potassium	5.2 mmol/L	3–6
Acid–base balance and metabolic parameters	pH	7.328	7.35–7.45
	pCO ₂	47.2 mm Hg	35–45
	Bicarbonate	24.9 mmol/L	22–26
	Base excess	–2.4 mmol/L	(–2)–(+2)
	Lactate	2.50 mmol/L	0.5–2.22
	Capillary blood glucose	11.6 mmol/L	7.8–11.1
Markers of infection	C-reactive protein	7.48 mg/dL	<5
	Peripheral blood smear	Toxic changes in neutrophils	
	Blood culture	No growth	

Table 2 Comparison of physical-chemical and microscopic findings of thoracentesis fluid, expressed breast milk and serum

Test	Thoracentesis fluid	Expressed breast milk	Serum
Appearance	Opalescent white	Opalescent white	Clear
Centrifugation	Remains uniform	Forms a creamy layer	–
pH	7.5 (7.4–7.8)	7.2	–
Benedict's test	Trace	Strongly positive	–
Glucose	2.0 mmol/L (2.7–11)	0.8 mmol/L	5.4 mmol/L
Protein	20 g/L (20–30)	14 g/L	33 g/L
Triglyceride	0.64 mmol/L (>1.24)	0.33 mmol/L	0.34 mmol/L
Total cholesterol	Undetectable (<5.17)	Undetectable	2.72 mmol/L
Fluid triglyceride-to-cholesterol ratio	>1 (>1.0)	–	–
Fluid-to-serum triglyceride ratio	1.9 (>1.0)	–	–
Fluid-to-serum cholesterol ratio	<1 (<1.0)	–	–
Microscopy	Cytology	A field full of lymphocytes (>1000 cells/ μ L)	–
	Cholesterol crystals	Absent	–

Reference limits for chyle are given within parentheses with the respective parameters.^{6–8}

OUTCOME AND FOLLOW-UP

The respiratory distress was relieved following thoracentesis and parenteral nutrition with keeping the baby nil-by-mouth. However, the baby expired 2 days later due to overwhelming sepsis.

DISCUSSION

Chyle is a non-inflammatory, alkaline, bacteriostatic fluid composed of immunoglobulins, lymphocytes and dietary lipids.^{6–8} The thoracic duct transports a comparatively large volume of chyle daily, resulting in a rapid, significant accumulation of fluid within the pleural cavity in case of disruption to the flow.⁹ The lymphatics from the lower half of the body converge behind the aorta to form the thoracic duct, which runs on the right side of the vertebral column, locating the largest part of the thoracic duct within the right hemithorax, explaining the reason for chylothorax being frequently right sided. During the natural course of chylothorax, a chyloma (collection of chyle below the pleura) develops, which eventually bursts through the pleura to accumulate within the pleural space.⁶ Clinical manifestations of chylothorax depend on the rate of chyle leakage and the duration of chylothorax. Rapid considerable chyle accumulation can lead to significant cardiorespiratory morbidity by creating a positive pressure within the pleural cavity, as observed in the index patient. When long-standing, due to chronic loss of lymphocytes and immunoglobulins, chylothorax can lead to immunodeficiency, while chronic loss of fat and fat-soluble vitamins leads to

malnutrition.⁶ However, infections rarely occur in the extravasated chyle due to its bacteriostatic nature.⁷

The diagnosis of chylothorax is based on the demonstration of chylomicrons and lymphocytes in the pleural fluid. The presence of chylomicrons can be confirmed by the elevated fluid triglyceride levels above the established cut-off limit of 1.24 mmol/L (110 mg/dL) or by the gold standard lipoprotein electrophoresis.^{6–8} Fluid triglyceride levels <0.56 mmol/L typically exclude chylothorax.¹⁰ Therefore, lipoprotein electrophoresis is essential, especially when the triglyceride levels are inconclusive (0.56–1.24 mmol/L or 50–110 mg/dL), as observed




Figure 3 Field full of lymphocytes on pleural fluid microscopy.




Figure 4 Lipoprotein electrophoresis of the pleural fluid vs lipoprotein electrophoresis of serum of a fasting adult (HDL: High density lipoprotein, VLDL: Very low density lipoprotein, LDL: Low density lipoprotein).

Table 3 Summary of the investigation findings and antibiotic therapy with the timeline

		D1	D2	D3/4	D5/6	D7/8	D9/10	D11	D12
Haemoglobin (g/L)		76	105	121	189	186	139	154	146
White blood cells ($\times 10^9/L$)		27.3	23.9	27.9	28.8	21.1	22.5	37.4	33.9
Neutrophils (%)		68	61.6	–	79.6	79.6	70.7	46.5	31.4
Lymphocytes (%)		27	14.1	–	16.7	16.7	17.8	17.1	16.5
Platelets ($\times 10^9/L$)		220	242	271	178	110	67	123	102
Aspartate transaminase (U/L)		141	–	68	–	–	46	–	–
Alanine transaminase (U/L)		17	–	17	–	–	18	–	–
Total bilirubin ($\mu\text{mol/L}$)		196	143	87	120	86	82	–	–
Albumin (g/L)		–	21	–	–	–	–	–	–
Globulin (g/L)		–	11	–	–	–	–	–	–
Creatinine ($\mu\text{mol/L}$)		113	131	114	177	177	160	131	–
Sodium (mmol/L)		148	153	148	137	135	138	–	–
Potassium (mmol/L)		5.1	3.7	4.5	4.2	2.8	4.2	–	–
C-reactive protein (mg/dL)		0.5	7.48	–	9.15	–	85.36	47.4	–
Blood culture findings		No growth	No growth	<i>Coliform</i> growth	–	<i>Staphylococcus</i> species	<i>Klebsiella pneumoniae</i>	<i>Klebsiella pneumoniae</i>	<i>Coliform</i> growth
Antibiotic therapy	Benzylpenicillin					Omitted			
	Gentamicin				Omitted				
	Meropenem								
	Flucloxacillin								
	Sulbactam								

Coloured cells indicate the dates on which each antibiotic was given.

in this patient.^{7 11} Identification of chylomicrons by lipoprotein electrophoresis is based on the separation of lipoprotein particles according to their charge and mass under an electrical field. Due to the low protein content, chylomicrons are uncharged and remain at the origin (point of application), while any other lipoproteins present will demonstrate electrophoretic mobility.

Diagnosing chylothorax in neonates and children poses a challenge due to the absence of a clear definition of chyle triglyceride level, especially if the infant is not on full enteral feeds, as may be the case in neonates. Adult values are often applied due to the lack of evidence, although they may not necessarily represent paediatric biochemistry. van Straaten *et al* and Büttiker *et al* suggested using a lower triglyceride limit (1.1 mmol/L) for chyle in the paediatric patients.^{8 12} In their study on paediatric chylothorax, Büttiker *et al* provided an amended definition to its diagnosis as pleural fluid triglyceride >1.1 mmol/L and an absolute cell count >1000 cells/ μL with a lymphocyte fraction $>80\%$ which other researchers had later applied.^{4 8} They further emphasised the need for a mandatory minimal oral fat intake to diagnose chylothorax, especially in newborn infants, as the distinction between chylous and non-chylous effusion becomes difficult without oral fat intake.⁸ However, food consumption and malnutrition being confounding factors with considerable variability, lowering the cut-off limit may not necessarily alleviate the diagnostic confusion. Maldonado *et al* noted that 14% of chylomicron positive pleural effusions had triglyceride levels <1.24 mmol/L irrespective of the patient's age, which they attributed to fasting/malnutrition.¹³ This fact highlights the importance of interpreting biochemical results in conjunction with the clinical scenario. As observed in the index patient, a critically ill neonate would have a lower-than-average fat intake leading to less chylomicron production, thus lower triglyceride levels in chyle than expected, which may still fail to meet the amended cut-off limit. Therefore, another approach to interpreting fluid biochemistry is to use 'ratios' for the diagnosis to compensate for any confounding factors.^{6–8} Suggested ratios for the diagnosis of chylothorax include fluid-to-serum

triglyceride ratio >1 , fluid-to-serum cholesterol ratio <1 , fluid triglyceride-to-cholesterol ratio >1 , which were demonstrated during the diagnostic workup in the index patient. On standing, chyle separates into three layers: a creamy uppermost layer with chylomicrons, a milky intermediate layer and a dependent layer with cellular elements; predominantly lymphocytes.¹⁴ Therefore, demonstrating low triglyceride levels in the infranatant of the centrifuged sample is another method to attribute the high fluid triglyceride levels to the chylomicrons that characteristically float due to their low density.

Given the similarities in the macroscopic appearance, pseudo-chylothorax, empyema and extravasated parenteral lipids administered via a central line are the other primary differential diagnoses in patients presenting with 'milky' pleural effusions. The onset of chylothorax is usually acute or subacute, whereas pseudo-chylothorax and empyema are insidious. Pseudo-chylothorax usually develops in long-standing pleural effusions due to cholesterol crystal formation without disturbance to the thoracic duct.⁶ Adding 1–2 mL of ethyl ether can clear the 'milky' appearance in pseudo-chylothorax but not in chylothorax, whereas in empyema, the turbidity is due to suspended pus cells, thus produces a clear supernatant following centrifugation.⁷ The characteristic findings of chylothorax, pseudo-chylothorax and empyema are compared in table 4.^{6–8 15–17}

During the biochemical analysis, the impact of high triglyceride on the analytical methods needs to be considered as triglyceride in the chylous fluid causes analytical interference by spectral interference, non-homogeneity of the sample and volume displacement effect. Spectral interferences may be alleviated by serial dilutions, analysis of the infranatant or using LipoClear (a liquid polymer reagent clearing lipaemia). Non-homogeneity and volume displacement may be lessened by centrifugation and using the infranatant with fewer chylomicrons for the analysis. Presence of lipids in the fluid results in spuriously high protein levels when using the sulfosalicylic acid method to analyse chylous fluid protein.

Table 4 Comparison of characteristic findings in three 'milky' pleural effusions

Test		Chylothorax	Pseudo-chylothorax	Empyema	
				Simple	Complicated
Macroscopy	Appearance		Opalescent white		
	Centrifugation	Forms a creamy upper layer	Remains uniform	Forms a clear supernatant	
	Addition of 1 mL of ether	Milky appearance remains	Milky appearance disappears	Milky appearance remains	
Lipid analysis	Triglyceride	>1.24 mmol/L (110 mg/dL)	<0.56 mmol/L (50 mg/dL)	Absent	
	Cholesterol	<5.17 mmol/L (200 mg/dL)	>5.17 mmol/L (200 mg/dL)	May present if long-standing	
	Fluid-to-serum triglyceride ratio	>1.0	<1.0	–	
	Fluid-to-serum cholesterol ratio	<1.0	>1.0	–	
	Fluid cholesterol/ triglyceride ratio	<1.0	>1.0	–	
	Lipoprotein electrophoresis	Chylomicrons present	No chylomicrons	–	
Biochemistry	Glucose	2.7–11 mmol/L	<2.2 mmol/L	>2.2 mmol/L	<2.2 mmol/L
	Total protein	20–30 g/L	<30 g/L	>30 g/L	
	pH	7.4–7.8	<7.35	>7.2	<7.2
	LDH	<2/3 x UNL	Variable	>2/3 x UNL (>1000 IU/L)	
Microscopy	Absolute cell count	>1000 cells/ μ L	Variable depending on underlying pathology	No/ few pus cells	>1000 cells/ μ L
	Lymphocytes	>80%			<10%
	Polymorphs	<20%			>90%
	Organisms	Absent	Organisms \pm	Absent	Organisms \pm
	Cholesterol crystals	Absent	Present	Absent	Present if long-standing
Culture		No growth	Depends on the pathology	No growth	Bacterial growth+

LDH, lactate dehydrogenase; UNL, upper normal limit (in the serum).

Congenital causes of neonatal chylothorax include congenital lymphatic malformations (pulmonary lymphangiomatosis, lymphangiectasia, thoracic duct atresia) and chylothorax-associated syndromes (such as Down, Noonan, Turner, Gorham-Stout, X-linked myotubular myopathy). Although up to 50% of neonatal chylothorax may be associated with a genetic syndrome, diagnosing a defined syndrome may be difficult.^{1–4} Acquired causes of neonatal chylothorax include thoracic surgical interventions and perinatal trauma due to hyperexpansion/stretching of the chest wall during resuscitation or birth.^{6–18, 19} Considering the clinical presentation, pleural effusion of traumatic chylothorax can have a latent period of 2–10 days, as observed in the index patient. In contrast, congenital chylothorax usually manifests antenatally as a space-occupying lesion restricting lung development, with 50% presenting with pleural effusion on day 1 of life.^{6, 8}

The initial management of chylothorax is aimed at patient stabilisation by draining the chylothorax to allow lung expansion, ventilatory support and replacement of fluid loss. Specific treatment includes medium-chain triglyceride (MCT) feeds and octreotide in the presence of continuous pleural fluid output. MCT is directly absorbed to portal circulation, bypassing lymphatics; thus, feeding MCT or keeping the patient nil-by-mouth with total parenteral feeding can resolve 50% of the cases.⁸ In the event of failure to respond to the above measures, identifying the site of rupture in the thoracic duct by lymphangiography and direct ligation of the duct is the definitive surgical management.^{6, 8} Despite available medical and surgical management options, neonatal chylothorax has a high mortality rate ranging between 20% and 60%, especially when associated with other comorbidities.^{4, 5} In congenital forms of neonatal chylothorax, high mortality rates are observed when associated with hydrops fetalis, whereas, in acquired forms of neonatal chylothorax, the prognosis is poor when associated with prematurity and infection as observed in the index patient.⁴ Further, the loss of lymphocytes and immunoglobulins in the chyle may have

contributed to the worsening of the sepsis in the index patient, which led to her demise, among other contributory factors.

The index case highlights that the applicability of the amended definition for paediatric chylothorax depends on the minimal oral fat intake; thus, it may not alleviate the dilemma faced during the diagnosis of neonatal chylothorax and chylothorax in malnourished/non-orally fed patients irrespective of their age. Therefore, in scenarios with inconclusive fluid triglyceride levels, ratios calculated based on fluid and serum triglyceride and cholesterol values may be conveniently applied in place of triglyceride cut-off values for the tentative diagnosis of chylothorax.

Learning points

- ▶ Although rare, chylothorax should be considered a primary differential diagnosis in perinatal pleural effusions.
- ▶ Applicability of triglyceride cut-off values in chylothorax depends on the minimal oral fat intake by the patient irrespective of age.
- ▶ In cases with inconclusive fluid triglyceride levels, fluid-to-serum triglyceride and cholesterol 'ratios' can be applied for the chylothorax diagnosis.

Acknowledgements We thank Dr Indika Neluwa-Liyanage, Lecturer, Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayawardenepura, for his expertise and assistance in critically reviewing the manuscript.

Contributors UDS participated in the patient management by planning, conducting and critical interpretation of laboratory investigations, designed and wrote the initial draft of the manuscript. RR provided clinical care for the patient and critically reviewed the manuscript. BKTPD participated in the patient management by critical interpretation of laboratory investigations and critically reviewed the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Udara Dilrukshi Senarathne <http://orcid.org/0000-0003-2329-6871>

REFERENCES

- Downie L, Sasi A, Malhotra A. Congenital chylothorax: associations and neonatal outcomes. *J Paediatr Child Health* 2014;50:234–8.
- Bialkowski A, Poets CF, Franz AR, et al. Congenital chylothorax: a prospective nationwide epidemiological study in Germany. *Arch Dis Child Fetal Neonatal Ed* 2015;100:F169–72.
- Sze SWP, Ng PC, Lam HS. Life-Threatening hemolytic anemia after intrapleural instillation of OK-432 for treatment of congenital chylothorax. *Neonatology* 2016;110:303–6.
- White MK, Bhat R, Greenough A. Neonatal Chylothoraces: a 10-year experience in a tertiary neonatal referral centre. *Case Rep Pediatr* 2019;2019:1–4.
- Bagur Krishnamurthy M, Malhotra A. Congenital chylothorax: current perspectives and trends. *Res Rep Neonatol* 2017;7:53–63.
- Tutor JD. Chylothorax in infants and children. *Pediatrics* 2014;133:722–33.
- McGrath EE, Blades Z, Anderson PB. Chylothorax: aetiology, diagnosis and therapeutic options. *Respir Med* 2010;104:1–8.
- Büttiker V, Fanconi S, Burger R. Chylothorax in children: guidelines for diagnosis and management. *Chest* 1999;116:682–7.
- Hillerdal G. Chylothorax and pseudochylothorax. *Eur Respir J* 1997;10:1157–62.
- Hooper C, Lee YCG, Maskell N, et al. Investigation of a unilateral pleural effusion in adults: British thoracic Society pleural disease guideline 2010. *Thorax* 2010;65 Suppl 2:ii4–17.
- Staats BA, Ellefson RD, Budahn LL, et al. The lipoprotein profile of chylous and nonchylous pleural effusions. *Mayo Clin Proc* 1980;55:700–4.
- van Straaten HL, Gerards LJ, Krediet TG. Chylothorax in the neonatal period. *Eur J Pediatr* 1993;152:2–5.
- Maldonado F, Hawkins FJ, Daniels CE, et al. Pleural fluid characteristics of chylothorax. *Mayo Clin Proc* 2009;84:129–33.
- Merrigan BA, Winter DC, O'Sullivan GC. Chylothorax. *Br J Surg* 1997;84:15–20.
- Soto-Martinez M, Massie J. Chylothorax: diagnosis and management in children. *Paediatr Respir Rev* 2009;10:199–207.
- Ahmed AEH, Yacoub TE. Empyema thoracis. *Clin Med Insights Circ Respir Pulm Med* 2010;4:CCRPM.S5066–8.
- Agrawal V, Sahn SA. Lipid pleural effusions. *Am J Med Sci* 2008;335:16–20.
- Dubin PJ, King IN, Gallagher PG. Congenital chylothorax. *Curr Opin Pediatr* 2000;12:505–9.
- Rocha G, Fernandes P, Rocha P, et al. Pleural effusions in the neonate. *Acta Paediatr* 2006;95:791–8.

Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <https://www.bmj.com/company/products-services/rights-and-licensing/permissions/>
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- ▶ Submit as many cases as you like
- ▶ Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ▶ Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

Customer Service

If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow